The influence of @entity1338 pretreatment on psychopathological, endocrine and respiratory effects of @entity23910 ( @entity23911 ) was characterized. @entity1 with @entity4697 (DSM-III-R) were given 50 micrograms @entity23911 i.v. at 1100 hours on 2 separate study days. In a randomized double-blind design they were additionally infused with 150 micrograms @entity1338 or placebo from 1040 to 1110 hours. After @entity23911 all @entity1 experienced symptom attacks. No effects of @entity1338 on @entity1503 were observed. After @entity23911 , in the @entity1338 condition the pituitary release of @entity3317 (ACTH) and prolactin was seemingly enhanced compared to placebo. Our results suggest that @entity23911 -induced @entity4697 attacks are not suppressible by presynaptic alpha-2 receptor stimulation. Moreover, they point to a synergistic postsynaptic action of @entity1338 to @entity23911 upon pituitary hormone secretion. The diverging sites of action might possibly explain the discrepancies of psychopathological alterations and stress hormone secretion.

Influence of @entity1338 on psychopathological, endocrine and respiratory effects of @entity23910 in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4697 :: ('MESH:D016584', 'Disease') :: ['panic', 'panic disorder'] @entity23911 :: ('5754', 'Gene') :: ['CCK-4'] @entity23910 :: ('MESH:D013758', 'Chemical') :: ['cholecystokinin tetrapeptide'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['panic psychopathology or blood gas parameters'] @entity3317 :: ('MESH:D000324', 'Chemical') :: ['adrenocorticotropin'] @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine']
@entity4697 :: (MESH:D016584,Disease) :: ['panic disorder']
